Keyword: Ascletis Pharmaceuticals

Gilead's Epclusa Chinese nod comes just a few weeks after Merck’s Zepatier, and AbbVie's Mavyret is close behind.

Takeda plans major cuts after $62 billion Shire buyout; Ascletis files for HK IPO under new listing rules; AZ hands Seroquel rights to Luye Pharma.

Chinese pharmaceutical database PharmCube highlighted 16 possible blockbuster approvals in China in 2018.

In 2017's first issue of FiercePharmaAsia weekly wrap-up, Takeda spends $35 million on a GI deal, Ascletis is armed with $100 million in the country's HCV drug race, Sanofi's dengue vaccine promotional effort is halted by the Philippines' FDA, fire at Sun Pharma's API plant killed two, and more.

Hepatitis C is a big problem in China, and drugmakers are still waiting on approval for their next-gen treatments. Now, regulators are promising action--and Gilead Sciences is pressing the accelerator.

Calls are growing on China to speed up approvals for newer hepatitis C therapies as well as pricing access formulas.

At least one of China's estimated 30 million hepatitis C-infected patients found a way to make a bootleg cocktail of hepatitis C therapies by patching together ingredients via online shopping.